Abstract Objective APPEASE is a phase I study to assess the safety. dosing. and efficacy of rivoceranib (a selective. small-molecule inhibitor of VEGFR2) in combination with pembrolizumab. https://www.chiggate.com/majirel-majicontrast-red-rouge-for-sale/